<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872232</url>
  </required_header>
  <id_info>
    <org_study_id>ROZETEL_RCT</org_study_id>
    <nct_id>NCT03872232</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan in Patients With Primary Hypercholesterolemia and Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of co-administrated
      Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and
      essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a phase 3 study to evaluate efficacy and safety of co-administrated
      Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and
      essential hypertension.

      In &quot;Rosuvastatin/Ezetimibe+Telmisartan&quot; treatment group, 60 subjects will be assigned and the
      subjects administer &quot;Rosuvastatin/Ezetimibe+Telmisartan&quot; for 8 weeks.

      In &quot;Rosuvastatin/Ezetimibe&quot; treatment group, 60 subjects will be assigned and the subjects
      administer &quot;Rosuvastatin/Ezetimibe&quot; for 8 weeks.

      In &quot;Telmisartan&quot; treatment group, 60 subjects will be assigned and the subjects administer
      &quot;Telmisartan&quot; for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">December 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>LDL-C change at Week 8 compared to Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MSSBP change at Week 8 compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>MSSBP change at Week 4 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>LDL-C change at Week 4 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sitting diastolic blood pressure (MSDBP)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>MSDBP change at Week 4, 8 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TC change at Week 4, 8 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>HDL-C change at Week 4, 8 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TG)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TG change at Week 4, 8 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein cholesterol/High density lipoprotein cholesterol (LDL-C/HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>LDL-C/HDL-C change at Week 4, 8 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol/High density lipoprotein cholesterol (TC/HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TC/HDL-C change at Week 4,8 compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Ezetimibe/Rosuvastatin and Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Ezetimibe/Rosuvastatin and Telmisartan&quot; for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe/Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Ezetimibe/Rosuvastatin&quot; for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Telmisartan&quot; for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/Rosuvastatin</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Ezetimibe/Rosuvastatin</arm_group_label>
    <arm_group_label>Ezetimibe/Rosuvastatin and Telmisartan</arm_group_label>
    <other_name>Rosuvamibe Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Ezetimibe/Rosuvastatin and Telmisartan</arm_group_label>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis Tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Subjects with hypertension and hyperlipidemia

        Exclusion Criteria:

          -  Patient with known or suspected secondary hypertension

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Soo Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

